Ibolya Czegle
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ibolya Czegle has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Miklós Csala
Department of Molecular Biology, Semmelweis University, Tűzoltó u. 37-47, H-1094 Budapest, Hungary
4 shared publications Angelo Benedetti
2 shared publications- Angelo Benedetti
Department of Molecular and Developmental Medicine, University of Siena, 53100 Siena, Italy
2 shared publications Gábor Bánhegyi
2 shared publicationsJózsef Mandl
Semmelweis University
2 shared publicationsRosella Fulceri
2 shared publications
Latest Publications
- 1 November 2015
- Published by Elsevier in Journal of Reproductive Immunology
- Vol. 112, 53-57
Increased circulating interleukin-17 levels in preeclampsia
- 1 November 2015
- Published by Elsevier in Journal of Reproductive Immunology
- Vol. 112, 53-57
Increased circulating interleukin-17 levels in preeclampsia
- 1 March 2013
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - General Subjects
- Vol. 1830 (3) , 2608-2618
Multiple roles of glucose-6-phosphatases in pathophysiology
- 1 March 2013
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - General Subjects
- Vol. 1830 (3) , 2608-2618
Multiple roles of glucose-6-phosphatases in pathophysiology
- Open Access
- 1 January 2012
- Published by Baishideng Publishing Group Inc. in World Journal of Hepatology
- Vol. 4 (4) , 129-38
G6PT-H6PDH-11βHSD1 triad in the liver and its implication in the pathomechanism of the metabolic syndrome
The metabolic syndrome, one of the most common clinical conditions in recent times, represents a combination of cardiometabolic risk determinants, including central obesity, glucose intolerance, insulin resistance, dyslipidemia, non-alcoholic fatty liver disease and hypertension. Prevalence of the metabolic syndrome is rapidly increasing worldwide as a consequence of common overnutrition and consequent obesity. Although a unifying picture of the pathomechanism is still missing, the key role of the pre-receptor glucocorticoid activation has emerged recently. Local glucocorticoid activation is catalyzed by a triad composed of glucose-6-phosphate-transporter, hexose-6-phosphate dehydrogenase and 11β-hydroxysteroid dehydrogenase type 1 in the endoplasmic reticulum. The elements of this system can be found in various cell types, including adipocytes and hepatocytes. While the contribution of glucocorticoid activation in adipose tissue to the pathomechanism of the metabolic syndrome has been well established, the relative importance of the hepatic process is less understood. This review summarizes the available data on the role of the hepatic triad and its role in the metabolic syndrome, by confronting experimental findings with clinical observations.
- 1 January 2012
- Published by Baishideng Publishing Group Inc. in World Journal of Hepatology
- Vol. 4 (4) , 129-38
Open AccessG6PT-H6PDH-11βHSD1 triad in the liver and its implication in the pathomechanism of the metabolic syndrome
The metabolic syndrome, one of the most common clinical conditions in recent times, represents a combination of cardiometabolic risk determinants, including central obesity, glucose intolerance, insulin resistance, dyslipidemia, non-alcoholic fatty liver disease and hypertension. Prevalence of the metabolic syndrome is rapidly increasing worldwide as a consequence of common overnutrition and consequent obesity. Although a unifying picture of the pathomechanism is still missing, the key role of the pre-receptor glucocorticoid activation has emerged recently. Local glucocorticoid activation is catalyzed by a triad composed of glucose-6-phosphate-transporter, hexose-6-phosphate dehydrogenase and 11β-hydroxysteroid dehydrogenase type 1 in the endoplasmic reticulum. The elements of this system can be found in various cell types, including adipocytes and hepatocytes. While the contribution of glucocorticoid activation in adipose tissue to the pathomechanism of the metabolic syndrome has been well established, the relative importance of the hepatic process is less understood. This review summarizes the available data on the role of the hepatic triad and its role in the metabolic syndrome, by confronting experimental findings with clinical observations.
- 1 December 2008
- Published by Akademiai Kiado Zrt. in Acta Physiologica Hungarica
- Vol. 95 (4) , 419-424
Different expression and distribution of 11β-hydroxysteroid dehydrogenase type 1 in obese and lean animal models of type 2 diabetes (Short communication)
11beta-hydroxysteroid dehydrogenase type 1 (11betaHSD1) is a NADPH dependent oxidoreductase of the endoplasmic reticulum lumen which converts cortisone to cortisol and plays a role in the pathogenesis of metabolic syndrome and type 2 diabetes. The aim of our study was to investigate the correlation between the expression/activity of 11betaHSDI and obesity. Liver and adipose tissue microsomes of an obese (Zucker) and a non-obese (Goto-Kakizaki) type 2 diabetes model rat strains were used. 11betaHSDI expression was detected at mRNA, protein and activity level. The activity of 11betaHSD1 was increased in the adipose tissue and decreased in the liver of the obese Zucker rat, while its mRNA levels were significantly different only in the adipose tissue. In diabetic Goto-Kakizaki rat both the expression and the activity of 11betaHSD1 were elevated in liver, but not in adipose tissue. These results suggest that the prereceptorial glucocorticoid activation is different in the liver and adipose tissue of the two diabetes models. This phenomenon might be responsible for the obese and lean phenotypes in type 2 diabetes.
- 1 December 2008
- Published by Akademiai Kiado Zrt. in Acta Physiologica Hungarica
- Vol. 95 (4) , 419-424
Different expression and distribution of 11β-hydroxysteroid dehydrogenase type 1 in obese and lean animal models of type 2 diabetes (Short communication)
11beta-hydroxysteroid dehydrogenase type 1 (11betaHSD1) is a NADPH dependent oxidoreductase of the endoplasmic reticulum lumen which converts cortisone to cortisol and plays a role in the pathogenesis of metabolic syndrome and type 2 diabetes. The aim of our study was to investigate the correlation between the expression/activity of 11betaHSDI and obesity. Liver and adipose tissue microsomes of an obese (Zucker) and a non-obese (Goto-Kakizaki) type 2 diabetes model rat strains were used. 11betaHSDI expression was detected at mRNA, protein and activity level. The activity of 11betaHSD1 was increased in the adipose tissue and decreased in the liver of the obese Zucker rat, while its mRNA levels were significantly different only in the adipose tissue. In diabetic Goto-Kakizaki rat both the expression and the activity of 11betaHSD1 were elevated in liver, but not in adipose tissue. These results suggest that the prereceptorial glucocorticoid activation is different in the liver and adipose tissue of the two diabetes models. This phenomenon might be responsible for the obese and lean phenotypes in type 2 diabetes.
- 1 September 2006
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 291 (3) , 511-517
Translocon pores in the endoplasmic reticulum are permeable to small anions
Contribution of translocon peptide channels to the permeation of low molecular mass anions was investigated in rat liver microsomes. Puromycin, which purges translocon pores of nascent polypeptides, creating additional empty pores, raised the microsomal uptake of radiolabeled UDP-glucuronic acid, while it did not increase the uptake of glucose-6-phosphate or glutathione. The role of translocon pores in the transport of small anions was also investigated by measuring the effect of puromycin on the activity of microsomal enzymes with intraluminal active sites. The mannose-6-phosphatase activity of glucose-6-phosphatase and the activity of UDP-glucuronosyltransferase were elevated upon addition of puromycin, but glucose-6-phosphatase and β-glucuronidase activities were not changed. The increase in enzyme activities was due to a better access of the substrates to the luminal compartment rather than to activation of the enzymes. Antibody against Sec61 translocon component decreased the activity of UDP-glucuronosyltransferase and antagonized the effect of puromycin. Similarly, the addition of the puromycin antagonist anisomycin or treatments of microsomes, resulting in the release of attached ribosomes, prevented the puromycin-dependent increase in the activity. Mannose-6-phosphatase and UDP-glucuronosyltransferase activities of smooth microsomal vesicles showed higher basal latencies that were not affected by puromycin. In conclusion, translationally inactive, ribosome-bound translocons allow small anions to cross the endoplasmic reticulum membrane. This pathway can contribute to the nonspecific substrate supply of enzymes with intraluminal active centers.
- 1 September 2006
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 291 (3) , 511-517
Translocon pores in the endoplasmic reticulum are permeable to small anions
Contribution of translocon peptide channels to the permeation of low molecular mass anions was investigated in rat liver microsomes. Puromycin, which purges translocon pores of nascent polypeptides, creating additional empty pores, raised the microsomal uptake of radiolabeled UDP-glucuronic acid, while it did not increase the uptake of glucose-6-phosphate or glutathione. The role of translocon pores in the transport of small anions was also investigated by measuring the effect of puromycin on the activity of microsomal enzymes with intraluminal active sites. The mannose-6-phosphatase activity of glucose-6-phosphatase and the activity of UDP-glucuronosyltransferase were elevated upon addition of puromycin, but glucose-6-phosphatase and β-glucuronidase activities were not changed. The increase in enzyme activities was due to a better access of the substrates to the luminal compartment rather than to activation of the enzymes. Antibody against Sec61 translocon component decreased the activity of UDP-glucuronosyltransferase and antagonized the effect of puromycin. Similarly, the addition of the puromycin antagonist anisomycin or treatments of microsomes, resulting in the release of attached ribosomes, prevented the puromycin-dependent increase in the activity. Mannose-6-phosphatase and UDP-glucuronosyltransferase activities of smooth microsomal vesicles showed higher basal latencies that were not affected by puromycin. In conclusion, translationally inactive, ribosome-bound translocons allow small anions to cross the endoplasmic reticulum membrane. This pathway can contribute to the nonspecific substrate supply of enzymes with intraluminal active centers.
- Open Access
- 1 February 2006
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 281 (8) , 4671-4677
Uncoupled Redox Systems in the Lumen of the Endoplasmic Reticulum
- 1 February 2006
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 281 (8) , 4671-4677
Open AccessUncoupled Redox Systems in the Lumen of the Endoplasmic Reticulum